APCCC 2024: Who Should Receive Chemotherapy Before PSMA Radioligand Therapy?
APCCC 2024, metastatic castration resistant prostate cancer (mCRPC), PSMA radioligand therapy, Docetaxel, cabazitaxel, 177Lu-PSMA-617, TROPIC trial, CARD trial, TAX327 trial, SWOG 9916 trial, PRESIDE trial, 68Ga-PSMA-11, 18F-FDG PET/CT, PSMAfore trial, VISION trial, PSMA expression.